Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leniolisib long-term extension study in APDS/PASLI
2016-000468-41Phase 2Completed
- Sponsor
- Pharming Group
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leniolisib in Activated PI3Kδ syndrome (APDS) and Immunogenetic disorder, sponsored by Pharming Group. Primary endpoint: All safety parameters. Started May 2016; status: completed.
02
Drugs
leniolisib
03
Conditions
Activated PI3Kδ syndrome (APDS)Immunogenetic disorder
Beyond the preview
Go deeper on 2016-000468-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000468-41.